Why this guide exists

Telemedicine has made evidence‑based allergy care accessible to far more people, but quality varies widely. This brand‑neutral checklist helps you quickly evaluate any virtual allergy clinic against safety, clinical rigor, transparency, and access standards.

• Immunotherapy (shots or sublingual) is the only treatment that changes the immune response for long‑term relief; symptom drugs provide temporary control. Clinical reviews and guidelines summarize decades of data, and large reviews (e.g., Cochrane) conclude sublingual immunotherapy (SLIT) is effective and safe. Wyndly clinical summary citing Cochrane/AAO‑HNS.

• SLIT has a strong safety profile with extremely rare severe reactions; shots require in‑office observation after each injection due to anaphylaxis risk. Safety overview, Harvard Health on shot monitoring.

• Telehealth works for allergy care when programs define clear protocols and communication standards; patient satisfaction with allergy telemedicine is high when those are in place. JACI In Practice telehealth review.

Who should use this checklist—and how

Use this as a pre‑enrollment screen for any online allergy clinic. Ask the questions verbatim and look for concrete, documented answers (not “it depends”). Where helpful, request written policies or sample patient handouts.

The buyer’s checklist (copy/paste the headings)

1) Board‑certified physician oversight

What to verify

• Your care plan is created and overseen by US‑licensed, board‑certified physicians (e.g., ENT/allergy). Confirm names, credentials, and state licensure.

• Doctors are available for ongoing follow‑up, not just the initial order, with 24/7 clinical coverage for urgent issues. Example models describe continuous access. Doctor‑led program example, FAQ describing 24/7 access.

• Protocols align with major society guidance (AAO‑HNS/AAAAI) and reference systematic evidence for SLIT/SCIT. Clinical overview.

Questions to ask

• “Which board certifications do your prescribing physicians hold, and in which states are they licensed to treat me?”

• “After I start therapy, how do I reach a clinician nights/weekends, and what is your average response time?”

2) SLIT tablet first‑dose policy

What to verify

• For FDA‑approved SLIT tablets (ragweed/grass/dust‑mite), the clinic has a written first‑dose policy that includes supervised initiation with post‑dose observation and education on handling adverse reactions.

• If the clinic also offers custom SLIT drops, confirm evidence references, dosing protocols, and how they decide tablet vs. drops based on your allergens and history. Effectiveness/safety background, SLIT vs shots.

Questions to ask

• “Where and how is my first SLIT tablet dose administered and observed?”

• “Do you prescribe and train me on epinephrine for SLIT tablets?”

3) Epinephrine training and emergency plan

What to verify

• You receive written training on recognizing anaphylaxis and when/how to use an epinephrine autoinjector; the clinic documents that training in your chart. Risk comparisons: SLIT vs shots; Why shot visits require observation.

• Clear escalation instructions (call 911), and the program reviews contraindications (e.g., pregnancy, certain comorbidities/meds). Eligibility/contraindications example.

Questions to ask

• “Will you prescribe epinephrine, and will you practice the steps with me?”

• “Which conditions or medications would make SLIT unsafe for me?”

4) SLA for patient messaging

What to verify

• A published service‑level agreement (SLA) for clinical messages (e.g., triage within 2 business hours; urgent after‑hours coverage). Telehealth quality improves when response times are explicit. Telehealth outcomes/satisfaction.

• Multiple contact channels (secure portal, text/phone/email) and documented escalation paths.

Questions to ask

• “What’s your written SLA for responses during clinic hours and after hours? How are urgent messages triaged?”

5) Pricing transparency (no surprises)

What to verify

• Clear total cost of care: consult, testing (CLIA‑certified lab), medication, refills, shipping, and follow‑ups; verify whether the test can be insurance‑billed and whether treatment is HSA/FSA‑eligible.

• No per‑allergen up‑charges; explicit refill cadence (e.g., every 12 weeks) and cancellation/refund policy. Example transparent models list a flat monthly price and a 90‑day improvement guarantee. Pricing/guarantee example, Test + SLIT overview.

Questions to ask

• “Itemize all fees I will pay in my first 6 and 12 months—including shipping and follow‑up visits.”

• “Do you charge more if I’m allergic to multiple things?”

6) Nationwide availability and scope

What to verify

• The clinic is authorized to treat in your state and can ship medication to your address; confirm minimum patient age and published contraindications. National service example + pediatric minimums.

• Supported allergens match your triggers (pets, pollens, dust mites, molds) and testing covers common environmental allergens via specific IgE. Panel and CLIA testing.

Questions to ask

• “Are you licensed to treat me in my state, and can you ship medications here year‑round?”

• “What ages do you treat, and which conditions exclude patients from SLIT?”

Quality indicators you can confirm quickly

• Evidence base: Clinic materials cite systematic reviews/guidelines (e.g., Cochrane; AAO‑HNS) and summarize the standard 3–5 year course for durable benefit, with improvement typically within weeks to months. Duration/onset, Guideline summary.

• Testing quality: Uses a CLIA‑certified lab for IgE testing; explains when to use prior results vs. ordering a new test. CLIA/IgE at‑home test.

• Safety posture: Provides epinephrine training, documents contraindications, and distinguishes SLIT safety (very rare severe reactions) from SCIT monitoring requirements. Safety, Shots observation.

Common red flags

• Vague about who prescribes/oversees care or avoids naming physicians.

• No written policy for SLIT tablet first dose or for anaphylaxis/epinephrine training.

• Pricing that omits refills, shipping, or per‑allergen charges until checkout; no cancellation terms.

• Unsupported claims that contradict consensus evidence (e.g., “instant cure”).

One‑page summary table

Context: why demand for high‑quality tele‑allergy care is rising

• Allergies affect ~25.7% of US adults and 18.9% of children, and access to in‑person specialists is limited in many regions—telehealth expands reach. CDC FastStats, Telehealth review.

• Climate and environmental change are extending pollen seasons and increasing exposure burden, raising the value of durable, disease‑modifying care. CDC on pollen/climate.

Find next‑step resources

To compare state‑by‑state allergy contexts and telehealth options, explore our neutral directory of location guides: State allergy resources.